Zenman Icon

Where are you viewing this site?

Map of Contents United States International

Value Assessment Committee (VAC)

Value Assessment Committees are implemented by hospitals to improve clinical outcomes, enhance quality, and reduce cost. The committee formally evaluates a new technology based on the value it brings to the patient and hospital. The cross-functional team typically consists of clinicians, finance, supply chain, nursing, quality, and other hospital administrators. The Angel® Catheter value proposition is based on strong clinical evidence as supported by the Angel® Catheter Pivotal Study, a cost-benefit economic position, and positive quality-metric impact.

bio2_infographics_modified_triangle

Clinical

Despite the high risk of PE, many critically ill patients are left unprotected due to elevated risks of bleeding and other injury-related complications.

  • 91% of traditional filters are placed after PE diagnosis
  • 57% of patients had a delay in the initiation of chemical prophylaxis greater than 24 hours
  • PEs occur despite current thromboembolic prophylaxis and 74% of patients had chemical prophylaxis before the occurrence of PE

Patients are often hypercoagulable:

  • Most trauma patients are hypercoagulable within the first 12 days
  • Risk of PE is elevated when patients are hypercoagulable
  • Patients are typically contraindicated to anticoagulants upon hospital admission
  • Many patients are left unprotected due to elevated risks of bleeding and injury-related complications

 

According to the American Journal of Surgery (2011), PEs occur early with peak incidence at day 2. The design of the Angel® Catheter allows for immediate, bedside placement without the need for fluoroscopy or transport from the ICU, ensuring that all patients are protected against clinically significant PE.

bio2_infographics_modified_time-to-pe

Economic

The Angel® Catheter combines the IVC filter functionality of PE protection and the procedural intuitiveness of a CVC. Using the Angel® Catheter allows more critically ill patients to be treated sooner. This reduces the number of PE events and the cost associated with treating those events.

Through its novel design, the device reduces the number of complications associated with traditional IVC filters (e.g., deployment, migration, fracture, unable to retrieve). Furthermore, the Angel® Catheter allows hospital resources to be optimized compared to typical placement of traditional IVC filters in the Interventional Radiology (IR) suite.

  • PE in trauma patients can cost at least $31,000
  • Pivotal Study showed 11% averted PE rate in patients with a cavogram
  • The Angel Catheter can decrease length of stay by 4.9 days

Quality

The Centers for Medicare & Medicaid Services (CMS) initiated a program to reward acute-care hospitals with incentive payments for the quality of care they provide to their Medicare beneficiaries. The Angel® Catheter will positively impact the following metrics:

bio2_infographics_modified_quality

Angel® Catheter VAC Package

If you are interested in learning more about the Angel® Catheter, or to request a health economics report specific to your facility, please complete the below form and we will have a representative contact you.